nach oben

Cancer and Metastasis Reviews

Erschienen in:

23.06.2018

Eicosanoids and HB-EGF/EGFR in cancer

verfasst von: Cheng-Chieh Yang, Kuo-Wei Chang

Erschienen in: Cancer and Metastasis Reviews | Ausgabe 2-3/2018

Einloggen, um Zugang zu erhalten

Abstract

Eicosanoids are bioactive lipids that play crucial roles in various pathophysiological conditions, including inflammation and cancer. They include both the COX-derived prostaglandins and the LOX-derived leukotrienes. Furthermore, the epidermal growth factor receptor (EGFR) pathways family of receptor tyrosine kinases also are known to play a central role in the tumorigenesis. Various antitumor modalities have been approved cancer treatments that target therapeutically the COX-2 and EGFR pathways; these include selective COX-2 inhibitors and EGFR monoclonal antibodies. Research has shown that the COX-2 and epidermal growth factor receptor pathways actively interact with each other in order to orchestrate carcinogenesis. This has been used to justify a targeted combinatorial approach aimed at these two pathways. Although combined therapies have been found to have a greater antitumor effect than the administration of single agent, this does not exempt them from the possible fatal cardiac effects that are associated with COX-2 inhibition. In this review, we delineate the contribution of HB-EGF, an important EGFR ligand, to the cardiac dysfunction related to decreased shedding of HB-EGF after COX-2/PGE2 inhibition. A better understanding of the molecular mechanisms underlying these cardiac side effects will make possible more effective regimens that use the dual-targeting approach.

Greene, E. R., Huang, S., Serhan, C. N., & Panigrahy, D. (2011). Regulation of inflammation in cancer by eicosanoids. Prostaglandins & Other Lipid Mediators, 96(1–4), 27–36. https://doi.org/10.1016/j.prostaglandins.2011.08.004.CrossRef

Kuhn, H., Banthiya, S., & van Leyen, K. (2015). Mammalian lipoxygenases and their biological relevance. Biochimica et Biophysica Acta, 1851(4), 308–330. https://doi.org/10.1016/j.bbalip.2014.10.002.CrossRefPubMed

Okuyama, T., Ishihara, S., Sato, H., Rumi, M. A., Kawashima, K., Miyaoka, Y., Suetsugu, H., Kazumori, H., Cava, C. F., Kadowaki, Y., Fukuda, R., & Kinoshita, Y. (2002). Activation of prostaglandin E2-receptor EP2 and EP4 pathways induces growth inhibition in human gastric carcinoma cell lines. The Journal of Laboratory and Clinical Medicine, 140(2), 92–102.CrossRef

Liu, W., Reinmuth, N., Stoeltzing, O., Parikh, A. A., Tellez, C., Williams, S., Jung, Y. D., Fan, F., Takeda, A., Akagi, M., Bar-Eli, M., Gallick, G. E., & Ellis, L. M. (2003). Cyclooxygenase-2 is up-regulated by interleukin-1 beta in human colorectal cancer cells via multiple signaling pathways. Cancer Research, 63(13), 3632–3636.PubMed

Zhu, M., Zhu, Y., & Lance, P. (2013). TNFalpha-activated stromal COX-2 signalling promotes proliferative and invasive potential of colon cancer epithelial cells. Cell Proliferation, 46(4), 374–381. https://doi.org/10.1111/cpr.12047.CrossRefPubMed

Glinghammar, B., Inoue, H., & Rafter, J. J. (2002). Deoxycholic acid causes DNA damage in colonic cells with subsequent induction of caspases, COX-2 promoter activity and the transcription factors NF-kB and AP-1. Carcinogenesis, 23(5), 839–845.CrossRef

Eberhart, C. E., Coffey, R. J., Radhika, A., Giardiello, F. M., Ferrenbach, S., & DuBois, R. N. (1994). Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology, 107(4), 1183–1188.CrossRef

de Groot, D. J., de Vries, E. G., Groen, H. J., & de Jong, S. (2007). Non-steroidal anti-inflammatory drugs to potentiate chemotherapy effects: from lab to clinic. Critical Reviews in Oncology/Hematology, 61(1), 52–69. https://doi.org/10.1016/j.critrevonc.2006.07.001.CrossRefPubMed

Zhu, Y., Hua, P., & Lance, P. (2003). Cyclooxygenase-2 expression and prostanoid biogenesis reflect clinical phenotype in human colorectal fibroblast strains. Cancer Research, 63(2), 522–526.PubMed

10.

Zhu, Y., Zhu, M., & Lance, P. (2012). Stromal COX-2 signaling activated by deoxycholic acid mediates proliferation and invasiveness of colorectal epithelial cancer cells. Biochemical and Biophysical Research Communications, 425(3), 607–612. https://doi.org/10.1016/j.bbrc.2012.07.137.CrossRefPubMed

11.

Zhu, Y., Zhu, M., & Lance, P. (2012). iNOS signaling interacts with COX-2 pathway in colonic fibroblasts. Experimental Cell Research, 318(16), 2116–2127. https://doi.org/10.1016/j.yexcr.2012.05.027.CrossRefPubMed

12.

Zhu, Y., Zhu, M., & Lance, P. (2012). IL1beta-mediated stromal COX-2 signaling mediates proliferation and invasiveness of colonic epithelial cancer cells. Experimental Cell Research, 318(19), 2520–2530. https://doi.org/10.1016/j.yexcr.2012.07.021.CrossRefPubMed

13.

Zhu, Y., Hua, P., Rafiq, S., Waffner, E. J., Duffey, M. E., & Lance, P. (2002). Ca2+− and PKC-dependent stimulation of PGE2 synthesis by deoxycholic acid in human colonic fibroblasts. American Journal of Physiology. Gastrointestinal and Liver Physiology, 283(3), G503–G510. https://doi.org/10.1152/ajpgi.00525.2001.CrossRefPubMed

14.

Chan, A. T., Ogino, S., & Fuchs, C. S. (2009). Aspirin use and survival after diagnosis of colorectal cancer. JAMA, 302(6), 649–658. https://doi.org/10.1001/jama.2009.1112.CrossRefPubMedPubMedCentral

15.

Park, S. W., Kim, H. S., Choi, M. S., Jeong, W. J., Heo, D. S., Kim, K. H., & Sung, M. W. (2011). The effects of the stromal cell-derived cyclooxygenase-2 metabolite prostaglandin E2 on the proliferation of colon cancer cells. The Journal of Pharmacology and Experimental Therapeutics, 336(2), 516–523. https://doi.org/10.1124/jpet.110.173278.CrossRefPubMed

16.

Kinzler, K. W., & Vogelstein, B. (1998). Landscaping the cancer terrain. Science, 280(5366), 1036–1037.CrossRef

17.

Sheng, H., Shao, J., Morrow, J. D., Beauchamp, R. D., & DuBois, R. N. (1998). Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Research, 58(2), 362–366.PubMed

18.

Poligone, B., & Baldwin, A. S. (2001). Positive and negative regulation of NF-kappaB by COX-2: roles of different prostaglandins. The Journal of Biological Chemistry, 276(42), 38658–38664. https://doi.org/10.1074/jbc.M106599200.CrossRefPubMed

19.

Han, C., Michalopoulos, G. K., & Wu, T. (2006). Prostaglandin E2 receptor EP1 transactivates EGFR/MET receptor tyrosine kinases and enhances invasiveness in human hepatocellular carcinoma cells. Journal of Cellular Physiology, 207(1), 261–270. https://doi.org/10.1002/jcp.20560.CrossRefPubMed

20.

Buchanan, F. G., Wang, D., Bargiacchi, F., & DuBois, R. N. (2003). Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor. The Journal of Biological Chemistry, 278(37), 35451–35457. https://doi.org/10.1074/jbc.M302474200.CrossRefPubMed

21.

Chang, S. H., Liu, C. H., Conway, R., Han, D. K., Nithipatikom, K., Trifan, O. C., Lane, T. F., & Hla, T. (2004). Role of prostaglandin E2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression. Proceedings of the National Academy of Sciences of the United States of America, 101(2), 591–596. https://doi.org/10.1073/pnas.2535911100.CrossRefPubMed

22.

Kamiyama, M., Pozzi, A., Yang, L., DeBusk, L. M., Breyer, R. M., & Lin, P. C. (2006). EP2, a receptor for PGE2, regulates tumor angiogenesis through direct effects on endothelial cell motility and survival. Oncogene, 25(53), 7019–7028. https://doi.org/10.1038/sj.onc.1209694.CrossRefPubMed

23.

Watanabe, K., Kawamori, T., Nakatsugi, S., Ohta, T., Ohuchida, S., Yamamoto, H., Maruyama, T., Kondo, K., Ushikubi, F., Narumiya, S., Sugimura, T., & Wakabayashi, K. (1999). Role of the prostaglandin E receptor subtype EP1 in colon carcinogenesis. Cancer Research, 59(20), 5093–5096.PubMed

24.

Mutoh, M., Watanabe, K., Kitamura, T., Shoji, Y., Takahashi, M., Kawamori, T., Tani, K., Kobayashi, M., Maruyama, T., Kobayashi, K., Ohuchida, S., Sugimoto, Y., Narumiya, S., Sugimura, T., & Wakabayashi, K. (2002). Involvement of prostaglandin E receptor subtype EP(4) in colon carcinogenesis. Cancer Research, 62(1), 28–32.PubMed

25.

Fujino, H., Xu, W., & Regan, J. W. (2003). Prostaglandin E2 induced functional expression of early growth response factor-1 by EP4, but not EP2, prostanoid receptors via the phosphatidylinositol 3-kinase and extracellular signal-regulated kinases. The Journal of Biological Chemistry, 278(14), 12151–12156. https://doi.org/10.1074/jbc.M212665200.CrossRefPubMed

26.

Pozzi, A., Yan, X., Macias-Perez, I., Wei, S., Hata, A. N., Breyer, R. M., Morrow, J. D., & Capdevila, J. H. (2004). Colon carcinoma cell growth is associated with prostaglandin E2/EP4 receptor-evoked ERK activation. The Journal of Biological Chemistry, 279(28), 29797–29804. https://doi.org/10.1074/jbc.M313989200.CrossRefPubMed

27.

Rigas, B., Goldman, I. S., & Levine, L. (1993). Altered eicosanoid levels in human colon cancer. The Journal of Laboratory and Clinical Medicine, 122(5), 518–523.PubMed

28.

McLemore, T. L., Hubbard, W. C., Litterst, C. L., Liu, M. C., Miller, S., McMahon, N. A., et al. (1988). Profiles of prostaglandin biosynthesis in normal lung and tumor tissue from lung cancer patients. Cancer Research, 48(11), 3140–3147.PubMed

29.

Wang, D., & Dubois, R. N. (2004). Cyclooxygenase-2: a potential target in breast cancer. Seminars in Oncology, 31(1 Suppl 3), 64–73.CrossRef

30.

Hambek, M., Baghi, M., Wagenblast, J., Schmitt, J., Baumann, H., & Knecht, R. (2007). Inverse correlation between serum PGE2 and T classification in head and neck cancer. Head & Neck, 29(3), 244–248. https://doi.org/10.1002/hed.20503.CrossRef

31.

Park, J. M., Kanaoka, Y., Eguchi, N., Aritake, K., Grujic, S., Materi, A. M., Buslon, V. S., Tippin, B. L., Kwong, A. M., Salido, E., French, S. W., Urade, Y., & Lin, H. J. (2007). Hematopoietic prostaglandin D synthase suppresses intestinal adenomas in ApcMin/+ mice. Cancer Research, 67(3), 881–889. https://doi.org/10.1158/0008-5472.CAN-05-3767.CrossRefPubMed

32.

Kim, J., Yang, P., Suraokar, M., Sabichi, A. L., Llansa, N. D., Mendoza, G., Subbarayan, V., Logothetis, C. J., Newman, R. A., Lippman, S. M., & Menter, D. G. (2005). Suppression of prostate tumor cell growth by stromal cell prostaglandin D synthase-derived products. Cancer Research, 65(14), 6189–6198. https://doi.org/10.1158/0008-5472.CAN-04-4439.CrossRefPubMed

33.

Carpenter, G. (2000). The EGF receptor: a nexus for trafficking and signaling. Bioessays, 22(8), 697–707. https://doi.org/10.1002/1521-1878(200008)22:8<697::AID-BIES3>3.0.CO;2-1.CrossRefPubMed

34.

Riese 2nd, D. J., & Stern, D. F. (1998). Specificity within the EGF family/ErbB receptor family signaling network. Bioessays, 20(1), 41–48. https://doi.org/10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V.CrossRefPubMed

35.

Krause, D. S., & Van Etten, R. A. (2005). Tyrosine kinases as targets for cancer therapy. The New England Journal of Medicine, 353(2), 172–187. https://doi.org/10.1056/NEJMra044389.CrossRefPubMed

36.

Yarden, Y., & Pines, G. (2012). The ERBB network: at last, cancer therapy meets systems biology. Nature Reviews. Cancer, 12(8), 553–563. https://doi.org/10.1038/nrc3309.CrossRefPubMed

37.

Mochizuki, S., & Okada, Y. (2007). ADAMs in cancer cell proliferation and progression. Cancer Science, 98(5), 621–628. https://doi.org/10.1111/j.1349-7006.2007.00434.x.CrossRefPubMed

38.

Kenny, P. A., & Bissell, M. J. (2007). Targeting TACE-dependent EGFR ligand shedding in breast cancer. The Journal of Clinical Investigation, 117(2), 337–345. https://doi.org/10.1172/JCI29518.CrossRefPubMedPubMedCentral

39.

Yoshizumi, M., Kourembanas, S., Temizer, D. H., Cambria, R. P., Quertermous, T., & Lee, M. E. (1992). Tumor necrosis factor increases transcription of the heparin-binding epidermal growth factor-like growth factor gene in vascular endothelial cells. The Journal of Biological Chemistry, 267(14), 9467–9469.PubMed

40.

Cheng, C. Y., Kuo, C. T., Lin, C. C., Hsieh, H. L., & Yang, C. M. (2010). IL-1beta induces expression of matrix metalloproteinase-9 and cell migration via a c-Src-dependent, growth factor receptor transactivation in A549 cells. British Journal of Pharmacology, 160(7), 1595–1610. https://doi.org/10.1111/j.1476-5381.2010.00858.x.CrossRefPubMedPubMedCentral

41.

Murthy, A., Defamie, V., Smookler, D. S., Di Grappa, M. A., Horiuchi, K., Federici, M., et al. (2010). Ectodomain shedding of EGFR ligands and TNFR1 dictates hepatocyte apoptosis during fulminant hepatitis in mice. The Journal of Clinical Investigation, 120(8), 2731–2744. https://doi.org/10.1172/JCI42686.CrossRefPubMedPubMedCentral

42.

Ellis, P. D., Hadfield, K. M., Pascall, J. C., & Brown, K. D. (2001). Heparin-binding epidermal-growth-factor-like growth factor gene expression is induced by scrape-wounding epithelial cell monolayers: involvement of mitogen-activated protein kinase cascades. The Biochemical Journal, 354(Pt 1), 99–106.CrossRef

43.

Iwamoto, R., & Mekada, E. (2000). Heparin-binding EGF-like growth factor: a juxtacrine growth factor. Cytokine & Growth Factor Reviews, 11(4), 335–344.CrossRef

44.

Fu, S., Bottoli, I., Goller, M., & Vogt, P. K. (1999). Heparin-binding epidermal growth factor-like growth factor, a v-Jun target gene, induces oncogenic transformation. Proceedings of the National Academy of Sciences of the United States of America, 96(10), 5716–5721.CrossRef

45.

Johnson, A. C., Murphy, B. A., Matelis, C. M., Rubinstein, Y., Piebenga, E. C., Akers, L. M., Neta, G., Vinson, C., & Birrer, M. (2000). Activator protein-1 mediates induced but not basal epidermal growth factor receptor gene expression. Molecular Medicine, 6(1), 17–27.CrossRef

46.

Miyamoto, S., Hirata, M., Yamazaki, A., Kageyama, T., Hasuwa, H., Mizushima, H., Tanaka, Y., Yagi, H., Sonoda, K., Kai, M., Kanoh, H., Nakano, H., & Mekada, E. (2004). Heparin-binding EGF-like growth factor is a promising target for ovarian cancer therapy. Cancer Research, 64(16), 5720–5727. https://doi.org/10.1158/0008-5472.CAN-04-0811.CrossRefPubMed

47.

Yotsumoto, F., Yagi, H., Suzuki, S. O., Oki, E., Tsujioka, H., Hachisuga, T., Sonoda, K., Kawarabayashi, T., Mekada, E., & Miyamoto, S. (2008). Validation of HB-EGF and amphiregulin as targets for human cancer therapy. Biochemical and Biophysical Research Communications, 365(3), 555–561. https://doi.org/10.1016/j.bbrc.2007.11.015.CrossRefPubMed

48.

McCarthy, S. A., Samuels, M. L., Pritchard, C. A., Abraham, J. A., & McMahon, M. (1995). Rapid induction of heparin-binding epidermal growth factor/diphtheria toxin receptor expression by Raf and Ras oncogenes. Genes & Development, 9(16), 1953–1964.CrossRef

49.

Svensson, K. J., Kucharzewska, P., Christianson, H. C., Skold, S., Lofstedt, T., Johansson, M. C., et al. (2011). Hypoxia triggers a proangiogenic pathway involving cancer cell microvesicles and PAR-2-mediated heparin-binding EGF signaling in endothelial cells. Proceedings of the National Academy of Sciences of the United States of America, 108(32), 13147–13152. https://doi.org/10.1073/pnas.1104261108.CrossRefPubMedPubMedCentral

50.

Szalad, A., Katakowski, M., Zheng, X., Jiang, F., & Chopp, M. (2009). Transcription factor Sp1 induces ADAM17 and contributes to tumor cell invasiveness under hypoxia. Journal of Experimental & Clinical Cancer Research, 28, 129. https://doi.org/10.1186/1756-9966-28-129.CrossRef

51.

Nakai, K., Yoneda, K., Moriue, T., Igarashi, J., Kosaka, H., & Kubota, Y. (2009). HB-EGF-induced VEGF production and eNOS activation depend on both PI3 kinase and MAP kinase in HaCaT cells. Journal of Dermatological Science, 55(3), 170–178. https://doi.org/10.1016/j.jdermsci.2009.06.002.CrossRefPubMed

52.

Sauer, L., Gitenay, D., Vo, C., & Baron, V. T. (2010). Mutant p53 initiates a feedback loop that involves Egr-1/EGF receptor/ERK in prostate cancer cells. Oncogene, 29(18), 2628–2637. https://doi.org/10.1038/onc.2010.24.CrossRefPubMedPubMedCentral

53.

Wu, W. K., Sung, J. J., Lee, C. W., Yu, J., & Cho, C. H. (2010). Cyclooxygenase-2 in tumorigenesis of gastrointestinal cancers: an update on the molecular mechanisms. Cancer Letters, 295(1), 7–16. https://doi.org/10.1016/j.canlet.2010.03.015.CrossRefPubMed

54.

Buchanan, F. G., Gorden, D. L., Matta, P., Shi, Q., Matrisian, L. M., & DuBois, R. N. (2006). Role of beta-arrestin 1 in the metastatic progression of colorectal cancer. Proceedings of the National Academy of Sciences of the United States of America, 103(5), 1492–1497. https://doi.org/10.1073/pnas.0510562103.CrossRefPubMedPubMedCentral

55.

Pai, R., Soreghan, B., Szabo, I. L., Pavelka, M., Baatar, D., & Tarnawski, A. S. (2002). Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nature Medicine, 8(3), 289–293. https://doi.org/10.1038/nm0302-289.CrossRefPubMed

56.

Yang, C. C., Tu, H. F., Wu, C. H., Chang, H. C., Chiang, W. F., Shih, N. C., Lee, Y. S., Kao, S. Y., & Chang, K. W. (2016). Up-regulation of HB-EGF by the COX-2/PGE2 signaling associates with the cisplatin resistance and tumor recurrence of advanced HNSCC. Oral Oncology, 56, 54–61. https://doi.org/10.1016/j.oraloncology.2016.03.010.CrossRefPubMed

57.

Ohtsu, H., Dempsey, P. J., & Eguchi, S. (2006). ADAMs as mediators of EGF receptor transactivation by G protein-coupled receptors. American Journal of Physiology. Cell Physiology, 291(1), C1–C10. https://doi.org/10.1152/ajpcell.00620.2005.CrossRefPubMed

58.

Oshima, H., Popivanova, B. K., Oguma, K., Kong, D., Ishikawa, T. O., & Oshima, M. (2011). Activation of epidermal growth factor receptor signaling by the prostaglandin E(2) receptor EP4 pathway during gastric tumorigenesis. Cancer Science, 102(4), 713–719. https://doi.org/10.1111/j.1349-7006.2011.01847.x.CrossRefPubMed

59.

Pai, R., Nakamura, T., Moon, W. S., & Tarnawski, A. S. (2003). Prostaglandins promote colon cancer cell invasion; signaling by cross-talk between two distinct growth factor receptors. The FASEB Journal, 17(12), 1640–1647. https://doi.org/10.1096/fj.02-1011com.CrossRefPubMed

60.

Zhang, X., Chen, Z. G., Choe, M. S., Lin, Y., Sun, S. Y., Wieand, H. S., Shin, H. J., Chen, A., Khuri, F. R., & Shin, D. M. (2005). Tumor growth inhibition by simultaneously blocking epidermal growth factor receptor and cyclooxygenase-2 in a xenograft model. Clinical Cancer Research, 11(17), 6261–6269. https://doi.org/10.1158/1078-0432.CCR-04-2102.CrossRefPubMed

61.

Roberts, H. R., Smartt, H. J., Greenhough, A., Moore, A. E., Williams, A. C., & Paraskeva, C. (2011). Colon tumour cells increase PGE(2) by regulating COX-2 and 15-PGDH to promote survival during the microenvironmental stress of glucose deprivation. Carcinogenesis, 32(11), 1741–1747. https://doi.org/10.1093/carcin/bgr210.CrossRefPubMed

62.

Cherukuri, D. P., Chen, X. B., Goulet, A. C., Young, R. N., Han, Y., Heimark, R. L., et al. (2007). The EP4 receptor antagonist, L-161,982, blocks prostaglandin E2-induced signal transduction and cell proliferation in HCA-7 colon cancer cells. Experimental Cell Research, 313(14), 2969–2979. https://doi.org/10.1016/j.yexcr.2007.06.004.CrossRefPubMedPubMedCentral

63.

Kurtova, A. V., Xiao, J., Mo, Q., Pazhanisamy, S., Krasnow, R., Lerner, S. P., Chen, F., Roh, T. T., Lay, E., Ho, P. L., & Chan, K. S. (2015). Blocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistance. Nature, 517(7533), 209–213. https://doi.org/10.1038/nature14034.CrossRefPubMed

64.

Krausova, M., & Korinek, V. (2014). Wnt signaling in adult intestinal stem cells and cancer. Cellular Signalling, 26(3), 570–579. https://doi.org/10.1016/j.cellsig.2013.11.032.CrossRefPubMed

65.

Castellone, M. D., Teramoto, H., Williams, B. O., Druey, K. M., & Gutkind, J. S. (2005). Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis. Science, 310(5753), 1504–1510. https://doi.org/10.1126/science.1116221.CrossRefPubMed

66.

McGee, J., & Fitzpatrick, F. (1985). Enzymatic hydration of leukotriene A4. Purification and characterization of a novel epoxide hydrolase from human erythrocytes. The Journal of Biological Chemistry, 260(23), 12832–12837.PubMed

67.

Dreyling, K. W., Hoppe, U., Peskar, B. A., Morgenroth, K., Kozuschek, W., & Peskar, B. M. (1986). Leukotriene synthesis by human gastrointestinal tissues. Biochimica et Biophysica Acta, 878(2), 184–193.CrossRef

68.

Hennig, R., Ding, X. Z., Tong, W. G., Schneider, M. B., Standop, J., Friess, H., Büchler, M. W., Pour, P. M., & Adrian, T. E. (2002). 5-Lipoxygenase and leukotriene B(4) receptor are expressed in human pancreatic cancers but not in pancreatic ducts in normal tissue. The American Journal of Pathology, 161(2), 421–428. https://doi.org/10.1016/S0002-9440(10)64198-3.CrossRefPubMedPubMedCentral

69.

Larre, S., Tran, N., Fan, C., Hamadeh, H., Champigneulles, J., Azzouzi, R., et al. (2008). PGE2 and LTB4 tissue levels in benign and cancerous prostates. Prostaglandins & Other Lipid Mediators, 87(1–4), 14–19. https://doi.org/10.1016/j.prostaglandins.2008.05.001.CrossRef

70.

Chen, X., Li, N., Wang, S., Wu, N., Hong, J., Jiao, X., Krasna, M. J., Beer, D. G., & Yang, C. S. (2003). Leukotriene A4 hydrolase in rat and human esophageal adenocarcinomas and inhibitory effects of bestatin. Journal of the National Cancer Institute, 95(14), 1053–1061.CrossRef

71.

Jeong, C. H., Bode, A. M., Pugliese, A., Cho, Y. Y., Kim, H. G., Shim, J. H., Jeon, Y. J., Li, H., Jiang, H., & Dong, Z. (2009). [6]-Gingerol suppresses colon cancer growth by targeting leukotriene A4 hydrolase. Cancer Research, 69(13), 5584–5591. https://doi.org/10.1158/0008-5472.CAN-09-0491.CrossRefPubMed

72.

Ohd, J. F., Wikstrom, K., & Sjolander, A. (2000). Leukotrienes induce cell-survival signaling in intestinal epithelial cells. Gastroenterology, 119(4), 1007–1018.CrossRef

73.

Matsuyama, M., Hayama, T., Funao, K., Kawahito, Y., Sano, H., Takemoto, Y., Nakatani, T., & Yoshimura, R. (2007). Overexpression of cysteinyl LT1 receptor in prostate cancer and CysLT1R antagonist inhibits prostate cancer cell growth through apoptosis. Oncology Reports, 18(1), 99–104.PubMed

74.

Braccioni, F., Dorman, S. C., O'Byrne, P. M., Inman, M. D., Denburg, J. A., Parameswaran, K., et al. (2002). The effect of cysteinyl leukotrienes on growth of eosinophil progenitors from peripheral blood and bone marrow of atopic subjects. The Journal of Allergy and Clinical Immunology, 110(1), 96–101.CrossRef

75.

Chung, J. W., Kim, G. Y., Mun, Y. C., Ahn, J. Y., Seong, C. M., & Kim, J. H. (2005). Leukotriene B4 pathway regulates the fate of the hematopoietic stem cells. Experimental & Molecular Medicine, 37(1), 45–50. https://doi.org/10.1038/emm.2005.6.CrossRef

76.

Wada, K., Arita, M., Nakajima, A., Katayama, K., Kudo, C., Kamisaki, Y., & Serhan, C. N. (2006). Leukotriene B4 and lipoxin A4 are regulatory signals for neural stem cell proliferation and differentiation. The FASEB Journal, 20(11), 1785–1792. https://doi.org/10.1096/fj.06-5809com.CrossRefPubMed

77.

Boehmler, A. M., Drost, A., Jaggy, L., Seitz, G., Wiesner, T., Denzlinger, C., Kanz, L., & Mohle, R. (2009). The CysLT1 ligand leukotriene D4 supports alpha4beta1- and alpha5beta1-mediated adhesion and proliferation of CD34+ hematopoietic progenitor cells. Journal of Immunology, 182(11), 6789–6798. https://doi.org/10.4049/jimmunol.0801525.CrossRef

78.

Modat, G., Muller, A., Mary, A., Gregoire, C., & Bonne, C. (1987). Differential effects of leukotrienes B4 and C4 on bovine aortic endothelial cell proliferation in vitro. Prostaglandins, 33(4), 531–538.CrossRef

79.

Kim, G. Y., Lee, J. W., Cho, S. H., Seo, J. M., & Kim, J. H. (2009). Role of the low-affinity leukotriene B4 receptor BLT2 in VEGF-induced angiogenesis. Arteriosclerosis, Thrombosis, and Vascular Biology, 29(6), 915–920. https://doi.org/10.1161/ATVBAHA.109.185793.CrossRefPubMed

80.

Steiner, D. R., Gonzalez, N. C., & Wood, J. G. (2001). Leukotriene B(4) promotes reactive oxidant generation and leukocyte adherence during acute hypoxia. J Appl Physiol (1985), 91(3), 1160–1167. https://doi.org/10.1152/jappl.2001.91.3.1160. CrossRef

81.

Tsopanoglou, N. E., Pipili-Synetos, E., & Maragoudakis, M. E. (1994). Leukotrienes C4 and D4 promote angiogenesis via a receptor-mediated interaction. European Journal of Pharmacology, 258(1–2), 151–154.CrossRef

82.

Tong, W. G., Ding, X. Z., Talamonti, M. S., Bell, R. H., & Adrian, T. E. (2005). LTB4 stimulates growth of human pancreatic cancer cells via MAPK and PI-3 kinase pathways. Biochemical and Biophysical Research Communications, 335(3), 949–956. https://doi.org/10.1016/j.bbrc.2005.07.166.CrossRefPubMed

83.

Mezhybovska, M., Wikstrom, K., Ohd, J. F., & Sjolander, A. (2006). The inflammatory mediator leukotriene D4 induces beta-catenin signaling and its association with antiapoptotic Bcl-2 in intestinal epithelial cells. The Journal of Biological Chemistry, 281(10), 6776–6784. https://doi.org/10.1074/jbc.M509999200.CrossRefPubMed

84.

Ihara, A., Wada, K., Yoneda, M., Fujisawa, N., Takahashi, H., & Nakajima, A. (2007). Blockade of leukotriene B4 signaling pathway induces apoptosis and suppresses cell proliferation in colon cancer. Journal of Pharmacological Sciences, 103(1), 24–32.CrossRef

85.

Yoo, M. H., Song, H., Woo, C. H., Kim, H., & Kim, J. H. (2004). Role of the BLT2, a leukotriene B4 receptor, in Ras transformation. Oncogene, 23(57), 9259–9268. https://doi.org/10.1038/sj.onc.1208151.CrossRefPubMed

86.

Paruchuri, S., Hallberg, B., Juhas, M., Larsson, C., & Sjolander, A. (2002). Leukotriene D(4) activates MAPK through a Ras-independent but PKCepsilon-dependent pathway in intestinal epithelial cells. Journal of Cell Science, 115(Pt 9), 1883–1893.PubMed

87.

Paruchuri, S., Broom, O., Dib, K., & Sjolander, A. (2005). The pro-inflammatory mediator leukotriene D4 induces phosphatidylinositol 3-kinase and Rac-dependent migration of intestinal epithelial cells. The Journal of Biological Chemistry, 280(14), 13538–13544. https://doi.org/10.1074/jbc.M409811200.CrossRefPubMed

88.

Choe, M. S., Zhang, X., Shin, H. J., Shin, D. M., & Chen, Z. G. (2005). Interaction between epidermal growth factor receptor- and cyclooxygenase 2-mediated pathways and its implications for the chemoprevention of head and neck cancer. Molecular Cancer Therapeutics, 4(9), 1448–1455. https://doi.org/10.1158/1535-7163.MCT-04-0251.CrossRefPubMed

89.

Mendelsohn, J., & Baselga, J. (2006). Epidermal growth factor receptor targeting in cancer. Seminars in Oncology, 33(4), 369–385. https://doi.org/10.1053/j.seminoncol.2006.04.003.CrossRefPubMed

90.

Oxnard, G. R., Arcila, M. E., Chmielecki, J., Ladanyi, M., Miller, V. A., & Pao, W. (2011). New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer. Clinical Cancer Research, 17(17), 5530–5537. https://doi.org/10.1158/1078-0432.CCR-10-2571.CrossRefPubMedPubMedCentral

91.

Wu, J. Y., Yu, C. J., Chang, Y. C., Yang, C. H., Shih, J. Y., & Yang, P. C. (2011). Effectiveness of tyrosine kinase inhibitors on “uncommon” epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer. Clinical Cancer Research, 17(11), 3812–3821. https://doi.org/10.1158/1078-0432.CCR-10-3408.CrossRefPubMed

92.

Laurent-Puig, P., Cayre, A., Manceau, G., Buc, E., Bachet, J. B., Lecomte, T., Rougier, P., Lievre, A., Landi, B., Boige, V., Ducreux, M., Ychou, M., Bibeau, F., Bouché, O., Reid, J., Stone, S., & Penault-Llorca, F. (2009). Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. Journal of Clinical Oncology, 27(35), 5924–5930. https://doi.org/10.1200/JCO.2008.21.6796.CrossRefPubMed

93.

Sartore-Bianchi, A., Di Nicolantonio, F., Nichelatti, M., Molinari, F., De Dosso, S., Saletti, P., et al. (2009). Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer. PLoS One, 4(10), e7287. https://doi.org/10.1371/journal.pone.0007287.CrossRefPubMedPubMedCentral

94.

Lu, Y., Shi, C., Qiu, S., & Fan, Z. (2016). Identification and validation of COX-2 as a co-target for overcoming cetuximab resistance in colorectal cancer cells. Oncotarget, 7(40), 64766–64777. https://doi.org/10.18632/oncotarget.8649. CrossRefPubMedPubMedCentral

95.

Rothwell, P. M., Wilson, M., Elwin, C. E., Norrving, B., Algra, A., Warlow, C. P., & Meade, T. W. (2010). Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet, 376(9754), 1741–1750. https://doi.org/10.1016/S0140-6736(10)61543-7.CrossRefPubMed

96.

Burn, J., Bishop, D. T., Chapman, P. D., Elliott, F., Bertario, L., Dunlop, M. G., Eccles, D., Ellis, A., Evans, D. G., Fodde, R., Maher, E. R., Moslein, G., Vasen, H. F. A., Coaker, J., Phillips, R. K. S., Bulow, S., Mathers, J. C., & for the International CAPP consortium. (2011). A randomized placebo-controlled prevention trial of aspirin and/or resistant starch in young people with familial adenomatous polyposis. Cancer Prevention Research (Philadelphia, Pa.), 4(5), 655–665. https://doi.org/10.1158/1940-6207.CAPR-11-0106.CrossRef

97.

Kim, B., & Giardiello, F. M. (2011). Chemoprevention in familial adenomatous polyposis. Best Practice & Research. Clinical Gastroenterology, 25(4–5), 607–622. https://doi.org/10.1016/j.bpg.2011.08.002.CrossRef

98.

Oshima, M., Dinchuk, J. E., Kargman, S. L., Oshima, H., Hancock, B., Kwong, E., Trzaskos, J. M., Evans, J. F., & Taketo, M. M. (1996). Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell, 87(5), 803–809.CrossRef

99.

Gupta, G. P., Nguyen, D. X., Chiang, A. C., Bos, P. D., Kim, J. Y., Nadal, C., Gomis, R. R., Manova-Todorova, K., & Massagué, J. (2007). Mediators of vascular remodelling co-opted for sequential steps in lung metastasis. Nature, 446(7137), 765–770. https://doi.org/10.1038/nature05760.CrossRefPubMed

100.

Limasale, Y. D., Tezcaner, A., Ozen, C., Keskin, D., & Banerjee, S. (2015). Epidermal growth factor receptor-targeted immunoliposomes for delivery of celecoxib to cancer cells. International Journal of Pharmaceutics, 479(2), 364–373. https://doi.org/10.1016/j.ijpharm.2015.01.016.CrossRefPubMed

101.

Banu, N., Buda, A., Chell, S., Elder, D., Moorghen, M., Paraskeva, C., Qualtrough, D., & Pignatelli, M. (2007). Inhibition of COX-2 with NS-398 decreases colon cancer cell motility through blocking epidermal growth factor receptor transactivation: possibilities for combination therapy. Cell Proliferation, 40(5), 768–779. https://doi.org/10.1111/j.1365-2184.2007.00459.x.CrossRefPubMed

102.

Dittmann, K. H., Mayer, C., Ohneseit, P. A., Raju, U., Andratschke, N. H., Milas, L., & Rodemann, H. P. (2008). Celecoxib induced tumor cell radiosensitization by inhibiting radiation induced nuclear EGFR transport and DNA-repair: a COX-2 independent mechanism. International Journal of Radiation Oncology, Biology, Physics, 70(1), 203–212. https://doi.org/10.1016/j.ijrobp.2007.08.065.CrossRefPubMed

103.

Chen, L., He, Y., Huang, H., Liao, H., & Wei, W. (2008). Selective COX-2 inhibitor celecoxib combined with EGFR-TKI ZD1839 on non-small cell lung cancer cell lines: in vitro toxicity and mechanism study. Medical Oncology, 25(2), 161–171. https://doi.org/10.1007/s12032-007-9015-1.CrossRefPubMed

104.

Kim, J., Kim, N., Park, J. H., Chang, H., Kim, J. Y., Lee, D. H., Kim, J. M., Kim, J. S., & Jung, H. C. (2013). The effect of helicobacter pylori on epidermal growth factor receptor-induced signal transduction and the preventive effect of celecoxib in gastric cancer cells. Gut Liver, 7(5), 552–559. https://doi.org/10.5009/gnl.2013.7.5.552.CrossRefPubMedPubMedCentral

105.

Qian, M., Qian, D., Jing, H., Li, Y., Ma, C., & Zhou, Y. (2014). Combined cetuximab and celecoxib treatment exhibits a synergistic anticancer effect on human oral squamous cell carcinoma in vitro and in vivo. Oncology Reports, 32, 1681–1688. https://doi.org/10.3892/or.2014.3334.CrossRefPubMed

106.

Li, N., Li, H., Su, F., Li, J., Ma, X., & Gong, P. (2015). Relationship between epidermal growth factor receptor (EGFR) mutation and serum cyclooxygenase-2 level, and the synergistic effect of celecoxib and gefitinib on EGFR expression in non-small cell lung cancer cells. International Journal of Clinical and Experimental Pathology, 8(8), 9010–9020.PubMedPubMedCentral

107.

Valverde, A., Penarando, J., Canas, A., Lopez-Sanchez, L. M., Conde, F., Hernandez, V., et al. (2015). Simultaneous inhibition of EGFR/VEGFR and cyclooxygenase-2 targets stemness-related pathways in colorectal cancer cells. PLoS One, 10(6), e0131363. https://doi.org/10.1371/journal.pone.0131363.CrossRefPubMedPubMedCentral

108.

Jalili, A., Pinc, A., Pieczkowski, F., Karlhofer, F. M., Stingl, G., & Wagner, S. N. (2008). Combination of an EGFR blocker and a COX-2 inhibitor for the treatment of advanced cutaneous squamous cell carcinoma. Journal der Deutschen Dermatologischen Gesellschaft, 6(12), 1066–1069. https://doi.org/10.1111/j.1610-0387.2008.06861.x.CrossRefPubMed

109.

Kao, J., Genden, E. M., Chen, C. T., Rivera, M., Tong, C. C., Misiukiewicz, K., et al. (2011). Phase 1 trial of concurrent erlotinib, celecoxib, and reirradiation for recurrent head and neck cancer. Cancer, 117(14), 3173–3181. https://doi.org/10.1002/cncr.25786.CrossRefPubMed

110.

Fu, S., Rivera, M., Ko, E. C., Sikora, A. G., Chen, C. T., Vu, H. L., et al. (2011). Combined inhibition of epidermal growth factor receptor and cyclooxygenase-2 as a novel approach to enhance radiotherapy. Journal of Cell Science and Therapy, 1(2).

111.

Shin, D. M., Zhang, H., Saba, N. F., Chen, A. Y., Nannapaneni, S., Amin, A. R., et al. (2013). Chemoprevention of head and neck cancer by simultaneous blocking of epidermal growth factor receptor and cyclooxygenase-2 signaling pathways: preclinical and clinical studies. Clinical Cancer Research, 19(5), 1244–1256. https://doi.org/10.1158/1078-0432.CCR-12-3149.CrossRefPubMedPubMedCentral

112.

Reckamp, K. L., Koczywas, M., Cristea, M. C., Dowell, J. E., Wang, H. J., Gardner, B. K., Milne, G. L., Figlin, R. A., Fishbein, M. C., Elashoff, R. M., & Dubinett, S. M. (2015). Randomized phase 2 trial of erlotinib in combination with high-dose celecoxib or placebo in patients with advanced non-small cell lung cancer. Cancer, 121(18), 3298–3306. https://doi.org/10.1002/cncr.29480. CrossRefPubMedPubMedCentral

113.

Kearney, P. M., Baigent, C., Godwin, J., Halls, H., Emberson, J. R., & Patrono, C. (2006). Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ, 332(7553), 1302–1308. https://doi.org/10.1136/bmj.332.7553.1302.CrossRefPubMedPubMedCentral

114.

Gomez Cerezo, J., Lubomirov Hristov, R., Carcas Sansuan, A. J., & Vazquez Rodriguez, J. J. (2003). Outcome trials of COX-2 selective inhibitors: global safety evaluation does not promise benefits. European Journal of Clinical Pharmacology, 59(2), 169–175. https://doi.org/10.1007/s00228-003-0579-1.CrossRefPubMed

115.

Mukherjee, D., Nissen, S. E., & Topol, E. J. (2001). Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA, 286(8), 954–959.CrossRef

116.

Pratico, D., & Dogne, J. M. (2009). Vascular biology of eicosanoids and atherogenesis. Expert Review of Cardiovascular Therapy, 7(9), 1079–1089. https://doi.org/10.1586/erc.09.91.CrossRefPubMed

117.

Iwamoto, R., & Mekada, E. (2006). ErbB and HB-EGF signaling in heart development and function. Cell Structure and Function, 31(1), 1–14.CrossRef

118.

Nanba, D., Mammoto, A., Hashimoto, K., & Higashiyama, S. (2003). Proteolytic release of the carboxy-terminal fragment of proHB-EGF causes nuclear export of PLZF. The Journal of Cell Biology, 163(3), 489–502. https://doi.org/10.1083/jcb.200303017.CrossRefPubMedPubMedCentral

119.

Kinugasa, Y., Hieda, M., Hori, M., & Higashiyama, S. (2007). The carboxyl-terminal fragment of pro-HB-EGF reverses Bcl6-mediated gene repression. The Journal of Biological Chemistry, 282(20), 14797–14806. https://doi.org/10.1074/jbc.M611036200.CrossRefPubMed

120.

Yeyati, P. L., Shaknovich, R., Boterashvili, S., Li, J., Ball, H. J., Waxman, S., Nason-Burchenal, K., Dmitrovsky, E., Zelent, A., & Licht, J. D. (1999). Leukemia translocation protein PLZF inhibits cell growth and expression of cyclin A. Oncogene, 18(4), 925–934. https://doi.org/10.1038/sj.onc.1202375.CrossRefPubMed

121.

Barna, M., Merghoub, T., Costoya, J. A., Ruggero, D., Branford, M., Bergia, A., Samori, B., & Pandolfi, P. P. (2002). Plzf mediates transcriptional repression of HoxD gene expression through chromatin remodeling. Developmental Cell, 3(4), 499–510.CrossRef

122.

McConnell, M. J., Chevallier, N., Berkofsky-Fessler, W., Giltnane, J. M., Malani, R. B., Staudt, L. M., & Licht, J. D. (2003). Growth suppression by acute promyelocytic leukemia-associated protein PLZF is mediated by repression of c-myc expression. Molecular and Cellular Biology, 23(24), 9375–9388.CrossRef

123.

Shaffer, A. L., Yu, X., He, Y., Boldrick, J., Chan, E. P., & Staudt, L. M. (2000). BCL-6 represses genes that function in lymphocyte differentiation, inflammation, and cell cycle control. Immunity, 13(2), 199–212.CrossRef

124.

Yoshida, T., Fukuda, T., Hatano, M., Koseki, H., Okabe, S., Ishibashi, K., Kojima, S., Arima, M., Komuro, I., Ishii, G., Miki, T., Hirosawa, S., Miyasaka, N., Taniguchi, M., Ochiai, T., Isono, K., & Tokuhisa, T. (1999). The role of Bcl6 in mature cardiac myocytes. Cardiovascular Research, 42(3), 670–679.CrossRef

125.

Senbonmatsu, T., Saito, T., Landon, E. J., Watanabe, O., Price Jr., E., Roberts, R. L., et al. (2003). A novel angiotensin II type 2 receptor signaling pathway: possible role in cardiac hypertrophy. The EMBO Journal, 22(24), 6471–6482. https://doi.org/10.1093/emboj/cdg637.CrossRefPubMedPubMedCentral

126.

Cook, M., Gould, A., Brand, N., Davies, J., Strutt, P., Shaknovich, R., Licht, J., Waxman, S., Chen, Z., & Gluecksohn-Waelsch, S. (1995). Expression of the zinc-finger gene PLZF at rhombomere boundaries in the vertebrate hindbrain. Proceedings of the National Academy of Sciences of the United States of America, 92(6), 2249–2253.CrossRef

127.

Yamazaki, S., Iwamoto, R., Saeki, K., Asakura, M., Takashima, S., Yamazaki, A., Kimura, R., Mizushima, H., Moribe, H., Higashiyama, S., Endoh, M., Kaneda, Y., Takagi, S., Itami, S., Takeda, N., Yamada, G., & Mekada, E. (2003). Mice with defects in HB-EGF ectodomain shedding show severe developmental abnormalities. The Journal of Cell Biology, 163(3), 469–475. https://doi.org/10.1083/jcb.200307035.CrossRefPubMedPubMedCentral

128.

Iwamoto, R., Yamazaki, S., Asakura, M., Takashima, S., Hasuwa, H., Miyado, K., Adachi, S., Kitakaze, M., Hashimoto, K., Raab, G., Nanba, D., Higashiyama, S., Hori, M., Klagsbrun, M., & Mekada, E. (2003). Heparin-binding EGF-like growth factor and ErbB signaling is essential for heart function. Proceedings of the National Academy of Sciences of the United States of America, 100(6), 3221–3226. https://doi.org/10.1073/pnas.0537588100.CrossRefPubMedPubMedCentral

129.

Gann, P. H., Manson, J. E., Glynn, R. J., Buring, J. E., & Hennekens, C. H. (1993). Low-dose aspirin and incidence of colorectal tumors in a randomized trial. Journal of the National Cancer Institute, 85(15), 1220–1224.CrossRef

130.

Baron, J. A., Cole, B. F., Sandler, R. S., Haile, R. W., Ahnen, D., Bresalier, R., McKeown-Eyssen, G., Summers, R. W., Rothstein, R., Burke, C. A., Snover, D. C., Church, T. R., Allen, J. I., Beach, M., Beck, G. J., Bond, J. H., Byers, T., Greenberg, E. R., Mandel, J. S., Marcon, N., Mott, L. A., Pearson, L., Saibil, F., & van Stolk, R. U. (2003). A randomized trial of aspirin to prevent colorectal adenomas. The New England Journal of Medicine, 348(10), 891–899. https://doi.org/10.1056/NEJMoa021735.CrossRefPubMed

131.

Benamouzig, R., Deyra, J., Martin, A., Girard, B., Jullian, E., Piednoir, B., Couturier, D., Coste, T., Little, J., & Chaussade, S. (2003). Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial. Gastroenterology, 125(2), 328–336.CrossRef

132.

Liao, X., Lochhead, P., Nishihara, R., Morikawa, T., Kuchiba, A., Yamauchi, M., Imamura, Y., Qian, Z. R., Baba, Y., Shima, K., Sun, R., Nosho, K., Meyerhardt, J. A., Giovannucci, E., Fuchs, C. S., Chan, A. T., & Ogino, S. (2012). Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. The New England Journal of Medicine, 367(17), 1596–1606. https://doi.org/10.1056/NEJMoa1207756.CrossRefPubMedPubMedCentral

133.

Tougeron, D., Sha, D., Manthravadi, S., & Sinicrope, F. A. (2014). Aspirin and colorectal cancer: back to the future. Clinical Cancer Research, 20(5), 1087–1094. https://doi.org/10.1158/1078-0432.CCR-13-2563.CrossRefPubMed

134.

Liska, F., Mancini, M., Krupkova, M., Chylikova, B., Krenova, D., Seda, O., et al. (2014). Plzf as a candidate gene predisposing the spontaneously hypertensive rat to hypertension, left ventricular hypertrophy, and interstitial fibrosis. American Journal of Hypertension, 27(1), 99–106. https://doi.org/10.1093/ajh/hpt156.CrossRefPubMed

135.

Thomas, C. M., Yong, Q. C., Seqqat, R., Chandel, N., Feldman, D. L., Baker, K. M., & Kumar, R. (2013). Direct renin inhibition prevents cardiac dysfunction in a diabetic mouse model: comparison with an angiotensin receptor antagonist and angiotensin-converting enzyme inhibitor. Clinical Science (London, England), 124(8), 529–541. https://doi.org/10.1042/CS20120448.CrossRef

Titel: Eicosanoids and HB-EGF/EGFR in cancer
verfasst von: Cheng-Chieh Yang
Kuo-Wei Chang
Publikationsdatum: 23.06.2018
Verlag: Springer US
Erschienen in: Cancer and Metastasis Reviews / Ausgabe 2-3/2018
Print ISSN: 0167-7659
Elektronische ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-018-9746-9

Neu im Fachgebiet Onkologie

16.04.2024 | Maligne primäre ZNS-Tumoren | Nachrichten

Springer Medizin

Eicosanoids and HB-EGF/EGFR in cancer

Abstract

Neu im Fachgebiet Onkologie

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Chemotherapie mit Hindernissen

Das Ende der vollständigen axillären Lymphknotendissektion

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2-3/2018

mPGES-1 and ALOX5/-15 in tumor-associated macrophages

Preface

The role of lipid signaling in the progression of malignant melanoma

Eicosanoids in prostate cancer

Bioactive lipid metabolism in platelet “first responder” and cancer biology

Role of autotaxin in cancer stem cells

Neu im Fachgebiet Onkologie

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Chemotherapie mit Hindernissen

Das Ende der vollständigen axillären Lymphknotendissektion

Update Onkologie